# Peter Harwin

> Peter Harwin is a post-ipo equity investor at Fairmount Funds Management backing Health Care. See 3 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [Fairmount Funds Management](https://shizune.co/investors/profile/fairmount-funds-management)
- Location: Greater Philadelphia Area, United States
- Total investments: 3
- Last investment: Nov 2025
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/peter-harwin-a9162a13/

Peter Harwin is a post-ipo equity investor at Fairmount Funds Management in Greater Philadelphia Area focused on Health Care and Biotechnology. Peter Harwin is the Co-Founder and Managing Member of Fairmount Funds Management. He attended Emory University in 2004.

## Contacts

5 contacts available for Peter Harwin: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/peter-harwin?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Therapeutics | 1 | 33% |
| Health Diagnostics | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Galecto | Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medicalneed. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform. | $284.9M | Post-IPO Equity | Nov 10, 2025 |  |
| Cogent Biosciences | Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety andefficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, Massachusetts. | $225M | Post-IPO Equity | Feb 13, 2024 |  |
| Cogent Biosciences | Cogent Biosciences uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, is expected to enter Phase I clinical testing in the coming months to assess safety andefficacy. Unum is seeking partners interested in using the ACTR technology to arm proprietary tumor-specific antibodies with a T-cell to improve their therapeutic potential. The company is headquartered in Cambridge, Massachusetts. | $104.4M | Post-IPO Equity | Jul 06, 2020 |  |

3 of 3 investments shown.

## Co-investors
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 3 deals together
- [Venrock Healthcare Capital Partners](https://shizune.co/investors/profile/venrock-healthcare-partners) — VC Fund, 3 deals together
- [Commodore Capital](https://shizune.co/investors/profile/commodore-capital) — VC Fund, 2 deals together
- [TCG Crossover](https://shizune.co/investors/profile/tcg-crossover) — VC Fund, 2 deals together
- [Acorn Bioventures](https://shizune.co/investors/profile/acorn-bioventures) — VC Fund, 1 deal together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together

## About Fairmount Funds Management

VC Fund · Philadelphia, United States

Fairmount Funds Management is a Philadelphia-based investment firm.

1 contacts available at Fairmount Funds Management.

| Name | Title | Profile |
| --- | --- | --- |
| Peter Harwin | Co-Founder and Managing Member | — |

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does Peter Harwin invest in?

Peter Harwin invests primarily in Health Care, Biotechnology and Medical startups, most often at Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Peter Harwin?

Public channels for Peter Harwin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Peter Harwin last invest?

The most recent investment recorded for Peter Harwin closed in Nov 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co